Wall Street analysts expect that Moderna Inc (NASDAQ:MRNA) will report ($0.46) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Moderna’s earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.43). The company is expected to issue its next quarterly earnings results on Wednesday, November 6th.
Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover Moderna.
Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The business had revenue of $13.08 million for the quarter, compared to the consensus estimate of $18.80 million.
Shares of MRNA traded down $1.06 during mid-day trading on Wednesday, hitting $14.25. 2,386,200 shares of the company traded hands, compared to its average volume of 1,570,917. The business has a 50-day moving average price of $15.88. Moderna has a 1 year low of $11.54 and a 1 year high of $29.79. The company has a market cap of $5.11 billion and a PE ratio of -2.88.
Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Read More: What is a Buy-Side Analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.